Sexual Health & Hormone Optimization
Oxytocin, PT-141/Bremelanotide, Testosterone & hCG FDA Status
Three of the four are components of approved drug products
Oxytocin, chorionic gonadotropin, bremelanotide and testosterone all sit in products that are on the US market today. Three of the four reach a statutory condition under section 503A. The fourth, chorionic gonadotropin, became a licensed biological product in 2020 and FDA has said the compounding exemptions do not reach it. This page sets out what we checked in September 2026 and what each approved label actually covers.
Three of the four substances are components of FDA-approved drug products. Oxytocin is the active ingredient in PITOCIN, bremelanotide is the active ingredient in VYLEESI, and testosterone is the active ingredient in several FDA-approved products, including DEPO-TESTOSTERONE. Because these substances are components of approved drugs, a 503A compounding pathway may potentially apply, but only if all applicable 503A requirements are met.
hCG is different. PREGNYL, an FDA-approved product containing human chorionic gonadotropin (hCG), was deemed a biologic license application (BLA) on March 23, 2020. FDA states that biological products subject to section 351 licensure are not eligible for the 503A or 503B compounding exemptions. Therefore, PREGNYL’s approval should not be treated as creating a 503A or 503B compounding pathway for hCG.
FDA approval of a drug component does not, by itself, make every compounded version permissible. For oxytocin, bremelanotide, and testosterone, the compounder must still satisfy the applicable 503A requirements, including restrictions concerning compounded products that are essentially copies of commercially available FDA-approved drugs. None of these four substances appears on the 503A Bulks List, 503B Bulks List, or FDA’s drug shortage list. Oxytocin and testosterone have appeared in FDA’s Category 1 503B nomination materials, but Category 1 status reflects FDA’s interim enforcement position and should not be confused with statutory eligibility.
Testosterone also has an additional regulatory requirement: it is a Schedule III controlled substance under federal law. Controlled-substance requirements therefore apply in addition to the applicable compounding requirements. This is for egulatory tracking only and it is not medical advice or legal advice.
WHAT THIS CATEGORY COVERS
Four Approved Molecules, Four Narrower Labels
Written for the clinic that has been told, “this one is FDA-approved,” and wants to know what that actually means. Phoenix Meds Inc. is a sourcing coordinator between licensed United States clinics and licensed pharmacies. We are not a pharmacy, clinic, prescriber, or legal counsel, and we do not dispense. We review the federal record, record what we find on the date of review, and report those findings to the clinic.
There is a simple mistake we see often. A substance that is not FDA-approved, or does not have the required regulatory status, is described as though there is a clear compounding pathway. The opposite mistake happens too. An FDA-approved product is treated as proof that a compounded version is permitted, or that the same ingredient can be used for whatever clinical purpose is being promoted.
That is not what FDA approval means. Each of the four molecules discussed here is found in a commercially available FDA-regulated product. Three are associated with approved drug applications, and one is a licensed biologic. We look at each one separately, including what FDA approved, what the label says, and where the approval does not answer the compounding or clinical-use question.
HOW WE SUPPORT CLINICS
Phoenix Meds Regulatory Support Model
Molecule and Product Held Apart
The Label’s Own Exclusions Quoted
Essentially-a-Copy Surfaced Early
Category 1 Read as What It Is
Controlled-Substance Status Flagged
Route and Origin Checked, Not Assumed
Regulatory Support Delivered
Clinic Benefits
✓ The application number every time
J018261, 210557, 085635. We ask which approved product a claim refers to, so the claim can be tested against that product’s own label.
✓ The indication not the headline
Approved for what, in whom. Each of these four labels answers that narrowly, and the narrow answer is the one that matters.✓ The copy restriction named
Why a marketed approved version makes the compounded route harder. Most summaries present it as the opposite.✓ Layers kept seperate
Statutory eligibility, interim enforcement policy, and approval are three different things. Two of these substances sit in the middle layer only.✓ Schedule III raised upfront
Testosterone carries obligations no peptide on this site carries. Better known before an order than after.✓ Sources you can reopen
Every label, list and regulation linked below with the date checked. A compliance lead can repeat the whole check.
Those apply to the record-keeping. They do not extend to lawfulness. A registration, a credential or a certificate of analysis tells you about an entity or a material; none of them establishes that a particular preparation satisfies a statutory condition. The compounding pharmacy and its counsel must independently determine whether a specific preparation satisfies the applicable federal and state requirements.
Sexual Health and Hormone Concerns in Clinical Practice
Clinics working in this area see patients with concerns such as low libido, reduced sexual desire, fertility problems, and symptoms associated with low testosterone. These are real clinical concerns and are often what brings someone to the clinic in the first place.
How a prescriber evaluates and treats those concerns is a clinical decision. It is separate from the regulatory question of whether a particular preparation can be compounded or supplied. The two can easily get mixed together when an FDA-approved product exists for the same active ingredient.
That distinction matters throughout this page. FDA approval applies to a specific product, for a specific indication and population, under the terms of its approved labeling. It does not make a compounded preparation the same product, and it does not make every clinical use of the ingredient an FDA-approved use.
The labels are specific. For example, VYLEESI is approved for acquired, generalized HSDD in premenopausal women and expressly states that it is not indicated for HSDD in postmenopausal women or men, or to enhance sexual performance. FDA-approved testosterone products likewise have defined indications rather than a blanket approval for every condition associated with low testosterone.
The Four Substances in This Category
Bremelanotide and PT-141: approved, and the label says who for
Bremelanotide is the active ingredient in VYLEESI (NDA 210557), which FDA initially approved in 2019. The FDA-approved indication is for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), subject to the limitations stated in the approved labeling.
The label specifically states that VYLEESI is not indicated for HSDD in postmenopausal women or men and is not indicated to enhance sexual performance.
Those limitations should not be treated as interchangeable with a general statement that bremelanotide is FDA-approved for male sexual dysfunction or for enhancement of sexual performance.
For compounding purposes, however, the existence of an FDA-approved product containing bremelanotide does not, by itself, establish that a particular compounded preparation qualifies for the section 503A or 503B exemptions. FDA’s compounding framework contains additional requirements concerning bulk drug substances and the compounded preparation itself.
FDA enforcement records have also addressed compounded drug products containing bremelanotide where the applicable requirements for the compounding exemptions were not met.
The FDA-approved status of VYLEESI should not be presented as blanket FDA approval of compounded bremelanotide preparations. The regulatory analysis must be performed for the particular preparation and the applicable compounding pathway.
Testosterone: approved narrowly, Schedule III, and a labelling change still in request
Testosterone is an FDA-approved active ingredient used in multiple prescription products and is a controlled substance under federal law. FDA states that testosterone products are approved for use in men who have low testosterone levels in conjunction with an associated medical condition. FDA also states that approved testosterone products are not approved for men with low testosterone who lack an associated medical condition.
The FDA labeling history also needs to be stated precisely.
On February 28, 2025, FDA announced class-wide labeling changes for testosterone products following its review of cardiovascular safety data. In June 2026, FDA subsequently requested additional labeling updates, including removal of the limitation stating that the safety and efficacy of testosterone replacement therapy for age-related hypogonadism had not been established. FDA’s current information describes those June 2026 actions as requested labeling updates.
Accordingly, it would be inaccurate to summarize the June 2026 action simply as FDA having newly approved testosterone for age-related low testosterone. The current labeling of the particular testosterone product remains the appropriate reference.
The existence of marketed testosterone products also makes the section 503A analysis more fact-specific. FDA’s compounding framework addresses bulk drug substances, approved products, USP/NF monographs, FDA lists, shortages and other statutory requirements.
For example, FDA records identify Depo-Testosterone as testosterone cypionate injection and document marketed presentations. The existence of those marketed products means that the commercially available product and copy analysis cannot simply be omitted when evaluating a compounded testosterone cypionate preparation.
Testosterone is not a substance for which the existence of an FDA-approved product alone answers the compounding question. The pharmacy should document the applicable compounding pathway and the product-specific regulatory analysis, including any applicable copy considerations.
Oxytocin: an approved obstetric injection
Oxytocin is the active ingredient in Pitocin (NDA 018261), an FDA-approved prescription injection. FDA records identify the product as Pitocin (Oxytocin Injection, USP), Synthetic.
The approved product is labeled for obstetric uses, including induction or improvement of uterine contractions when medically indicated and management of uterine contractions after delivery. The approved labeling also distinguishes medically indicated induction from elective induction.
The existence of an FDA-approved oxytocin injection should not be read as FDA having evaluated every compounded oxytocin formulation, route of administration, or use.
For compounding purposes, the relevant analysis includes the applicable section 503A or 503B requirements, the status of the bulk drug substance, applicable USP/NF requirements, and the relationship between the compounded preparation and commercially available products. FDA states that the rules governing bulk drug substances differ between sections 503A and 503B.
The fact that the finished Pitocin product is described as “oxytocin injection, USP” should also not, by itself, be treated as proof that a separate statutory bulk-drug-substance monograph requirement has been satisfied.
Pitocin’s FDA approval establishes the status of the approved product. It does not, standing alone, establish eligibility of a particular compounded oxytocin preparation under sections 503A or 503B.
Chorionic gonadotropin (hCG): approved, human-derived, and outside the compounding exemptions
Chorionic gonadotropin is the active ingredient in products including Pregnyl. FDA’s records identify Pregnyl under former NDA 017692 and identify chorionic gonadotropin products among the biological products whose approved NDAs were deemed to be BLAs on March 23, 2020.
This transition is significant for compounding.
FDA states that, beginning March 23, 2020, biological products that transitioned from approved applications under the Federal Food, Drug, and Cosmetic Act to licenses under section 351 of the Public Health Service Act are not eligible for the exemptions for compounded drugs under sections 503A and 503B. FDA specifically identified human chorionic gonadotropin among the bulk drug substances affected by this transition.
Accordingly, the fact that chorionic gonadotropin appears in a historically approved drug application should not be presented as establishing ordinary 503A or 503B bulk-substance eligibility.
There is a separate FDA framework concerning the mixing, diluting, or repackaging of certain licensed biological products outside the scope of their approved labeling. That is a different regulatory question from compounding a drug from bulk chorionic gonadotropin and should not be conflated with it.
There is also a separate provision concerning certain animal-origin chorionic gonadotropin products. That issue should be analyzed independently from the March 23, 2020 biological-product transition.
The March 23, 2020 transition is the key regulatory distinction for chorionic gonadotropin. The existence of a former NDA does not, by itself, provide a current section 503A or 503B compounding pathway for bulk human chorionic gonadotropin. Any different regulatory theory should be supported by the specific FDA authority applicable to the preparation being considered.
HCG has been marketed for weight loss, although FDA has not approved HCG for weight loss. The approved labeling states that HCG has not been demonstrated to be effective as adjunctive therapy in the treatment of obesity and that there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction.
The approved label’s statements on obesity are quoted above. Our Weight Loss & Metabolic page covers that category’s own substances and their separate federal regulatory position.
This page describes regulatory issues and FDA source material; it is not a legal opinion or a determination that a particular compounded drug is lawful or unlawful. The regulatory analysis depends on the specific preparation, source, formulation, prescribing circumstances, pharmacy status, applicable federal requirements, and applicable state law.
EVIDENCE
What the Approved Labels Establish
Where the evidence is strongest
For each of these substances, FDA has approved at least one drug product containing the substance for a defined indication and population. Each approval reflects FDA’s review of the evidence submitted for that particular product, indication, and population.
That evidence is real, and it is also bounded. It supports the approved product for the indication and population described in its labeling. It does not, by itself, establish the safety or effectiveness of a different preparation containing the same substance, or establish safety or effectiveness for uses or populations outside the approved labeling.
Where the labels say the evidence is absent
Three of the four approved labels expressly identify limits relevant to the evidence.
VYLEESI states that it is not indicated for HSDD in postmenopausal women or in men and is not indicated to enhance sexual performance.
Pitocin states that the available data are inadequate to evaluate the benefit-to-risk considerations for elective induction of labor and therefore is not indicated for elective induction.
The HCG labeling states that HCG has not been demonstrated to be effective as adjunctive therapy in the treatment of obesity and that there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction.
These statements come from FDA-approved labeling and describe specific boundaries or limitations identified by the agency. They should not be expanded into broader claims about the safety or effectiveness of other preparations, populations, or uses.
Why Clinics Have Explored These Compounds
These substances are part of conversations that clinics and patients encounter in practice. The fact that an FDA-approved product exists for a particular substance can make the regulatory picture appear straightforward when it is not.
An FDA-approved product establishes the status of that particular product, its approved indication, and its labeling. It does not, by itself, establish that a compounded preparation containing the same substance qualifies for an exemption under section 503A or 503B.
The existence of a marketed FDA-approved product can also make the commercially available product and “essentially a copy” provisions relevant to the compounding analysis. FDA has separate requirements and guidance addressing these provisions under sections 503A and 503B.
None of the above is a recommendation to use these compounds. Any clinical decision, including whether a compounded preparation is appropriate for an individual patient, rests with the treating prescriber and must be considered in accordance with applicable federal and state requirements.
CATEGORY-SPECIFIC TRAPS
Four Questions Specific to This Category
“FDA-approved” describes a product, not a molecule
Every claim in this category should be tested against one question: approved product, or approved molecule?
PITOCIN is an FDA-approved product. Oxytocin is the active ingredient in that product. A compounded oxytocin preparation is not the FDA-approved Pitocin product and is not, by virtue of that approval alone, covered by Pitocin’s approval. The same distinction applies to the other substances discussed on this page.
Ask which FDA-approved product the statement refers to and, where applicable, for its application number. That number identifies a specific application and its approved labeling, which is publicly available. A supplier who cannot provide that information has left the claim difficult to verify.
An approved product on the market can make the copy provisions relevant
The existence of a commercially available or approved product can be important to the compounding analysis. Under section 503A, one of the conditions for the exemption concerns compounding regularly or in inordinate amounts of drug products that are essentially copies of commercially available drug products. FDA has issued separate guidance explaining this provision.
Section 503B contains a separate restriction: a compounded drug product must not be essentially a copy of one or more approved drug products, subject to the conditions and exceptions described in the statute and FDA’s guidance.
FDA’s guidance also distinguishes commercially available products from products that have been discontinued or are on the FDA drug shortages list. The precise analysis therefore depends on the applicable compounding pathway, the product involved, its current commercial status, and the characteristics of the compounded preparation.
A labeling request is not a labeling change
On June 18, 2026, FDA requested updates to testosterone prescribing information, including removal of the limitation stating that the safety and efficacy of testosterone replacement therapy in men with age-related hypogonadism had not been established. FDA describes these as requested labeling updates.
A request should not be described as a completed labeling change. The appropriate reference is the current labeling of the particular testosterone product being evaluated.
This page's category name is not a statement of approved use
“Sexual Health & Hormone” describes the clinical subject of this page. It does not describe what each product is FDA-approved to treat.
For example, Pitocin’s approved indications are obstetric, while Pregnyl’s approved labeling includes indications involving prepubertal cryptorchidism, hypogonadotropic hypogonadism in males, and induction of ovulation in certain anovulatory infertile women. Neither product’s approval is established simply by placing it under a broader category heading.
The way a product is described, advertised, and presented can be relevant to an assessment of intended use. Federal regulations recognize that objective intent may be shown by expressions, labeling, advertising, and circumstances surrounding distribution.
For that reason, the category on this site is organized around the questions clinics may have, while each substance’s FDA-approved indication is addressed separately. Where the category heading and an approved indication differ, the heading does not expand the approved indication.
A clinic should read the individual product section and its labeling rather than infer an approved use from the category name.
What to Verify Before Any Sourcing Decision
Against the statutory criteria. For compounding from bulk under section 503A, the statute provides three alternative bases for a bulk drug substance: an applicable USP or NF monograph; use as a component of an FDA-approved drug, where the applicable statutory conditions are met; or inclusion on the 503A Bulks List. The substance must also satisfy the other applicable requirements of section 503A. For section 503B, a bulk drug substance must be on the 503B Bulks List or, at the applicable time, be used in a drug that appears on FDA’s drug-shortage list, subject to the other requirements of section 503B. Meeting the bulk-substance condition alone does not establish eligibility for the applicable compounding exemption.
On essentially a copy. Determine how the pharmacy addresses the essentially-a-copy restriction for the specific preparation. Section 503A restricts regular or inordinate compounding of drug products that are essentially copies of commercially available drug products, subject to the statutory conditions. Section 503B separately provides that a compounded drug product may not be essentially a copy of one or more approved drug products, subject to the statutory conditions and exceptions. The analysis depends on the applicable compounding section, the comparable commercial or approved product, its status, and the characteristics of the compounded preparation.
On the route the order actually travels. If the pharmacy is relying on section 503A, the statute requires compounding for an identified individual patient based on receipt of a valid prescription order, with a limited provision permitting certain quantities to be compounded before receipt of that order when there is an established history of receiving valid prescriptions for the individual patient. The transaction should therefore be evaluated against the specific 503A provision being relied upon. If neither provision applies, the 503A exemption should not be assumed. Section 503B operates under a separate statutory framework.
On the label. Obtain the application number and review the current FDA-approved labeling for the particular product, including its indication, limitations of use, and labeling date. FDA approval applies to a particular product under a particular application and approved labeling. It should not be treated as approval of every preparation containing the same active ingredient or of uses outside that labeling.
On hCG specifically. Establish the regulatory status of the particular chorionic gonadotropin product or substance before applying a 503A or 503B analysis. FDA stated that, beginning March 23, 2020, certain biological products that transitioned from approved applications under the FD&C Act to licenses under section 351 of the Public Health Service Act were no longer eligible for the exemptions for compounded drugs under sections 503A and 503B. FDA specifically identified human chorionic gonadotropin among the affected biological products. The applicable status should therefore be established from the particular product or substance involved rather than inferred from a certificate of analysis.
On controlled-substance obligations, for testosterone. Testosterone is a Schedule III controlled substance under federal law. The applicable controlled-substance requirements, including DEA registration and recordkeeping requirements where applicable, as well as state controlled-substance requirements, should be addressed by the parties responsible for the relevant activities.
On the material. A certificate of analysis is evidence concerning the identity, strength, quality, purity, or other tested characteristics of a material. It does not, by itself, establish that a compounded preparation qualifies for an exemption under section 503A or 503B. Quality documentation and statutory eligibility are separate questions.
On labelling language. “Research Use Only” does not, by itself, determine a product’s status under the FD&C Act. Under 21 CFR 201.128, objective intent may be shown by expressions, the design or composition of an article, or the circumstances surrounding its distribution. The regulation also identifies labeling, advertising, and oral or written statements as evidence relevant to intended use.
FDA applied this principle in a June 17, 2026 warning letter to Wholesale Peptide in Brooksville, Florida. FDA stated that the firm’s “RESEARCH USE ONLY” and “NOT FOR HUMAN CONSUMPTION” statements did not control the analysis because other evidence, including the firm’s website and product descriptions, demonstrated intended use as drugs for humans. That warning letter concerned the firm and products addressed in the letter; it does not itself establish a violation by another firm.
The practical point is narrower: a disclaimer should not be evaluated in isolation. Product descriptions, claims, advertising, labeling, and the circumstances of distribution can all be relevant to an intended-use analysis. A testosterone listing that makes claims about age-related treatment, or an hCG listing that makes weight-loss claims, therefore warrants review against the applicable FDA-approved labeling and the broader circumstances in which the product is offered.
State Requirements
Everything above concerns federal law. State pharmacy boards, medical practice acts, prescribing and dispensing rules, and facility requirements may impose additional requirements. They do not replace applicable federal requirements. State boards have primary day-to-day oversight of most state-licensed pharmacies, and state law can affect matters such as pharmacy licensure, compounding, dispensing, office-use distribution, and controlled substances. The exact requirements vary by state.
Testosterone adds another layer because it is a Schedule III controlled substance under federal law, while states may impose additional controlled-substance requirements. We do not characterize any particular state’s rules here. A clinic should establish the requirements that apply in its state, including with its applicable state board and qualified counsel, before relying on a particular sourcing or dispensing arrangement.
Sourcing Coordination Through Phoenix Meds
Sourcing position, September 2026
This category requires a substance-specific review. An FDA-approved product containing a substance does not, by itself, establish the status of a compounded preparation containing that substance. For oxytocin, bremelanotide, and testosterone, our review identified FDA-approved drug products containing those substances. Chorionic gonadotropin is treated separately because of its regulatory status as a biological product. The details and FDA sources for each substance are set out in the sections below. Where the applicable requirements can be established for a particular transaction, Phoenix Meds may coordinate sourcing through appropriately licensed pharmacy partners. Our review considers the relevant FDA status, applicable compounding requirements, approved labeling, and other requirements relevant to the transaction.
We do not treat a supplier’s representation, an FDA application number, or a Category 1 entry as, by itself, establishing that a particular compounded preparation satisfies all applicable requirements. Category 1 status under FDA’s 503B interim policy is not the same as inclusion on the final 503B Bulks List.
A pharmacy’s licensure, registration, participation in a transaction, or willingness to dispense does not, by itself, establish that a particular preparation satisfies all applicable federal and state requirements. Phoenix Meds does not make that determination.
We review this section when relevant FDA regulations, policies, lists, or approved labeling change.
Verify This Yourself
Drugs@FDA — application 017692 — PREGNYL, holder Organon, and the statement “deemed to be a BLA on March 23, 2020”.
FDA — Notice to Compounders, 23 March 2020 — transitioning biologics “will not be eligible for the exemptions for compounded drugs under sections 503A and 503B”, and hCG is one of the four named.
PREGNYL current labelling, rev. 03/2025 — human origin, the three indications, the capitalised obesity statements. Supersedes the 2011 labelling.
Drugs@FDA — application 018261 — PITOCIN, sponsor PH Health, approved 19 November 1980, shown currently marketed.
PITOCIN current labelling — labeler Par Health USA, updated 12 August 2024; the elective-induction statement, unchanged from the 2014 version.
Drugs@FDA — application 210557 — bremelanotide acetate, sponsor Cosette, approved 21 June 2019, shown currently marketed.
VYLEESI approved labelling — the indication and the section 1 Limitations of Use quoted above.
Drugs@FDA — application 085635 — DEPO-TESTOSTERONE cypionate, Pfizer: 100 and 200 mg/mL prescription, 50 mg/mL discontinued.
FDA — Testosterone Information — both quoted sentences on what the approvals do and do not cover.
FDA — class-wide labelling changes, 28 February 2025 — the age-related Limitation of Use retained at that date.
FDA labelling request, 18 June 2026 — a request to sponsors, not a completed change.
21 CFR 1308.13(f)(84) — testosterone in Schedule III, the provision reaching salts, esters and ethers.
Related Clinic Resources
Legal & Regulatory Status Overview
— how 503A and 503B differ, what the bulks lists are, and how we report a finding rather than a legal conclusion.
Growth Hormone & Lean Body Composition
— sermorelin raises the same approved-drug-component question, with the opposite marketing status: its approved product was discontinued.
Weight Loss & Metabolic
— where hCG weight claims are usually aimed, and that category’s own federal position.
Sourcing Coordination
— how verification-gated coordination works and what we ask before any order.
Oxytocin, Pregnyl hCG, PT-141 and testosterone each have a product page on this site. Those pages are listings. This page carries the federal record, and where a listing and this page differ, this page is the one we maintain against the sources and the listing is the one that gets corrected. A listing is not a representation that a preparation satisfies section 503A or 503B, and it is not a statement that any approved product’s labelling extends to it.
Disclaimer and regulatory scope:
This page is regulatory information for licensed clinics, compiled from public FDA materials. It is not medical or legal advice, and not a determination that any product or preparation is lawful.
On the federal sources reviewed in September 2026, we identified a potential 503A basis for oxytocin, bremelanotide, and testosterone because each is a component of an FDA-approved drug. This does not by itself establish 503A compliance, and the statutory “essentially a copy” restrictions must also be considered where a commercially available FDA-approved product is marketed. For chorionic gonadotropin (hCG), we did not identify a 503A or 503B basis for compounding from bulk based on the sources reviewed. That is our finding on those sources at that time, not a legal conclusion.
State pharmacy law and medical practice acts apply on top, and testosterone is a Schedule III controlled substance. For how 503A and 503B differ and what the bulk lists are, see our Legal & Regulatory Status Overview. Clinics should consult qualified counsel in their state.
Phoenix Meds Inc. is not a pharmacy, clinic, prescriber, or medical provider, and we do not dispense. We coordinate sourcing between licensed clinics and licensed pharmacies. The pharmacy or outsourcing facility prepares, dispenses, and ships; any clinical decision rests with the prescriber.